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ABSTRACT 
A number of new nitric oxide (NO)-precursors were synthesized by grafting nitrate-containing 
moieties on the structures of the benzyloxy isonipecotanilide derivatives 1 and 2 already reported as 
moderately potent antiplatelet agents. Various nitrooxy (ONO2)-alkyl side chains were covalently 
linked to the piperidine nitrogen of the parent compounds through carbamate and amide linkage, and 
the synthesis of a benzyl nitrate analog (15) of compound 1 was also achieved. The in vitro 
vasodilatory activities, as well as platelet anti-aggregatory effects, of the newly synthesized organic 
nitrates were assessed. The (ONO2)methyl carbamate-based derivative 5a and the benzyl nitrate 
analog 15, which on the other hand retain activity as inhibitors of ADP-induced platelet aggregation, 
exhibited strong NO-mediated vasodilatory effects on pre-contracted rat aorta strips, with EC50 values 
in the low nanomolar range (13 and 29 nM, respectively). Experiments carried out with the selectively 
inhibited soluble guanylate cyclase (sGC), which is the key enzyme of the NO-mediated pathway 
leading to vascular smooth muscle relaxation, confirmed the involvement of NO in the observed 
vasodilation. The nitrate derivatives proved to be stable in acidic aqueous solution and at pH 7.4. In 
human serum, unlike 5a, which showed not to undergo enzyme-catalyzed decomposition, the other 
tested (ONO2)-alkyl carbamate-based compounds (5b and 5e) and benzyl nitrate 15 underwent a 
faster degradation. However, their decomposition rates in serum were quite slow (t½ > 2.6 h), which 
suggests that nitrate moiety is poorly metabolized in blood plasma and that much of the in vitro anti-
platelet activity has to be attributed to the intact (ONO2)-containing molecules. 
 
 
Keywords: Isonipecotamides; Nitrooxy alkyl carbamate derivatives; Nitric oxide-donors; 
Vasodilation; Antiplatelet activity. 
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Abbreviations: AChE, acetylcholinesterase; ADP, adenosine 5’-diphosphate; BuChE, 
butyrylcholinesterase; cGMP, cyclic guanosine monophosphate; CHF, congestive heart failure; 
CINOD, cyclooxygenase-inhibiting nitric oxide donator; GSH, glutathione; GST, glutathione S-
transferase; GTN, glyceryl trinitrate; ISDN, isosorbide dinitrate; MLC, myosin light chain; MLCK, 
MLC kinase; NO, nitric oxide; ODQ, 1H-[1,2,4]oxadiazolo[4,3-a]quinaxolin-1-one; PON1, 
paraoxonase; PRP, platelet rich plasma; RP-HPLC, reversed phase-high performance liquid 
chromatography; sGC, soluble guanylated cyclase. 
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1. Introduction 
The organic nitrates are known for over a century as coronary artery medications, since the use of 
glyceryl trinitrate (GTN) as anti-anginal drug (Münzel et al., 2014). Administered through 
transdermal and sublingual routes, GTN is an essential medication in angina, acute myocardial 
infarction, severe hypertension, and coronary artery spasm. Isosorbide dinitrate (ISDN, Fig. 1) is 
another long-acting nitrate reported in the World Health Organization’s List of Essential Medicines 
(WHO, 2013), used for heart-related chest pain and congestive heart failure (CHF) as adjunct to other 
drugs. 
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Fig. 1. Organic nitrates used in clinics and some representative experimental NO-donor drugs. 
 
GTN and ISDN, which undergo denitration in vivo with production of the active metabolite nitric 
oxide (NO), act primarily via vascular smooth muscle relaxation, with decrease of cardiac output and 
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improvement of myocardial oxygen supply-to-demand ratio without affecting the heart’s 
contractions. 
The mechanism by which nitrovasodilators liberate NO in the body has not been completely 
elucidated. Nonenzymatic pathways involving endogenous sulfhydryl-containing molecules 
(Harrison, 2005) and several enzymes, such as the cytosolic glutathione S-tranferase (GST), xanthine 
oxidoreductase (XO), the mitochondrial aldehyde dehydrogenase, or the microsomal cytochrome 
P450 (CYP), have been proposed as mediators of bioactivation of organic nitrates (Chen et al., 2002; 
DiFabio et al., 2003; Keen et al., 1976; Kollau et al., 2005; Kurz et al., 1993; McDonald and Bennett, 
1990; Schroder, 1992; Servent et al., 1989; Taylor et al., 1989). The released NO activates the soluble 
guanylate cyclase (sGC) (Follmann et al., 2013), thereby increasing the formation of cyclic guanosine 
monophoshate (cGMP), which, in turn, activates the myosin light chain kinase (MLCK), the enzyme 
phosphorylating MLC in the presence of ATP, ultimately preventing the phosphorylation of myosin 
and resulting in vascular muscle relaxation (Lucas et al., 2000; Murad, 2006; Sogo et al., 2000). 
Endogenous NO, generated from L-arginine by the nitric oxide synthase (NOS) enzymes, has several 
different physiological actions targeted at kidney, reproductive apparatus, immunity system, 
inflammation, and neurotransmission (Gasco et al., 2005; Scatena et al., 2010). In the cardiovascular 
system NO predominates in large conduits, which supports its primarily anti-atherothrombotic effects 
(Miller et al., 2008, 2000; Miller and Megson, 2007; Schade et al., 2010). NO contributes to control 
the vascular endothelium smooth muscle cells tone and platelets’ adhesion and aggregation (Miller 
and Megson, 2007; Moncada et al., 1991; Murad, 2006; Scatena et al., 2010; Schade et al., 2010). 
Besides GTN and ISDN, nicorandil (Fig. 1) has been marketed in several countries as a vasodilatory 
medication for the treatment of angina pectoris and CHF. As a hybrid between organic nitrates and 
K+-ATP channel agonists, it acts through dual mechanism of action, combining the vasodilatory 
property of both nitrates and nicotinamide with its ability to increase K+ conductance (Edwards and 
Weston, 1990; Horinaka, 2011). 
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In the last decades a lot of hybrid nitrates as in vivo NO-donors have been studied for their potential 
use in the treatment of a variety of diseases, including pain and inflammation, thrombosis and 
restenosis, neurodegenerative diseases, cancer, liver disease, impotence, bronchial asthma and 
osteoporosis (Keeble and Moore, 2002). Since some disagreement about whether nitrates really 
generate NO at all, some authors prefer to use the term NO-mimetics (Thatcher et al., 2005). 
However, among the various pharmacologically relevant families of nitrate-containing agents (Fig. 
1), NO-aspirin showed pharmacological effects in cardiovascular, cancer and inflammation models, 
and when tested in clinical trials showed little or no gastric toxicity (Cena et al., 2003; Keeble and 
Moore, 2002), due to gastro-protective effects of NO (Lazzarato et al., 2009). A new class of 
cyclooxygenase-inhibiting nitric oxide donors (CINODs) has been developed with the aim of 
achieving greater safety than the existing non-steroidal anti-inflammatory drug (NSAIDs) (Boschi et 
al., 2010, 2009). Two promising CINODs are HCT-1026 and HTC-3012 (Fig. 1), i.e., 4-(ONO2)butyl 
esters of flurbiprofen and naproxen, respectively. HCT-1026 has been under study for its therapeutic 
use in a variety of conditions, including neurodegeneration and inflammation (Keeble and Moore, 
2002; Scatena et al., 2005; Gasparini et al., 2005; Prosperi et al., 2004; Wenk et al., 2004, 2002; 
Ronchetti et al., 2009; Idris et al., 2004). HTC-3012, as single (S)-enantiomer, has been tested in 
clinical trials for the treatment of osteoarthritis (Geusens, 2009; Zhang et al., 2011). Other typical 
examples of NO-donor hybrids of existing drugs have been reported, which include ACE-inhibitors, 
statins, calcium antagonists, and phosphodiesterase inhibitors (Martelli et al., 2006; Napoli and 
Ignarro, 2003; Serafim et al., 2012). 
Some years ago, we have reported a number of moderately potent isonipecotamide-based inhibitors 
of adenosine 5’-diphosphate (ADP)-induced human platelet aggregation (de Candia et al., 2003). 
Among them, N-(3-(4-fluorobenzyloxy)phenyl)piperidine-4-carboxamide 1 (Fig. 2), with half 
maximal inhibitory concentration (IC50) of 68 μM, and the N-(3-[(3’,5’-difluoro-1,1’-biphenyl-4-
yl)methoxy]phenyl) analog 2 (IC50 = 27 μM), which proved to be an antiplatelet agent about two-fold 
more potent than 1 (de Candia et al., 2009), and a potent factor Xa (fXa)-selective inhibitor (Ki = 130 
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nM) as well, were chosen for further optimization through hybridization with the organic nitrate 
moiety, the first aim being to possibly strengthen the in vivo antiplatelet activity of the parent 
compounds 1 and 2, conferring to them additional NO-mediated vasorelaxing properties. 
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Fig. 2. Fluorinated benzyloxyphenyl piperidine-4-carboxamide derivatives endowed with anti-
thrombotic properties (de Candia et al., 2009). Both compounds proved to inhibit ADP-induced 
platelet aggregation (IC50 equals 68 and 27 µM for 1 and 2, respectively), whereas 2 showed 
additional nanomolar inhibition potency against blood coagulation factor Xa (Ki = 135 nM). 
 
 
In this work, we grafted nitrate moieties on the structures of antiplatelet compounds 1 and 2, by 
covalently linking various nitrooxy (ONO2)-alkyl side chains to the piperidine nitrogen via carbamate 
and amide linkages. A benzyl nitrate analog of compound 1 was also synthesized. The in vitro 
vasodilatory and antiplatelet activities of the newly synthesized compounds were evaluated, and the 
stability in aqueous solutions and human serum of the most potent compounds was assessed. 
 
2. Materials and methods 
Triethylamine (TEA), dichloromethane (DCM), chloroform, ethanol (EtOH), methanol (MeOH), 
acetone (Me2CO), ethyl acetate (EtOAc), n-hexane (Hex), acetonitrile (ACN), N,N-
dimethylformamide (DMF), tetrahydrofuran (THF), trifluoroacetic acid (TFA), sodium sulphate 
(Na2SO4), sodium bicarbonate (NaHCO3), potassium carbonate (K2CO3), silver nitrate (AgNO3), 
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deuterated dimethyl sulfoxide (DMSO-d6) and deuterated chloroform (CDCl3) and all other 
chemicals and reagents were purchased from Sigma-Aldrich (Milan, Italy). Unless otherwise stated, 
chemicals and reagents were of analytical grade and were used without further purification. 
Melting points were determined by using the capillary method on a Stuart Scientific SMP3 
electrothermal apparatus and are not corrected. IR spectra were recorded using KBr disks on a Perkin-
Elmer Spectrum One FT-IR spectrophotometer (Perkin-Elmer Ltd., Buckinghamshire, UK), and the 
most significant absorption bands expressed in cm-1 are listed. 1H NMR spectra were recorded at 
300MHz on a Varian Mercury 300 instrument. Chemical shift values are expressed in δ and the 
coupling constants J in Hz. Abbreviations are as follows: s, singlet; d, doublet; t, triplet; q, quartet, 
dd, doublet of doublets; m, multiplet; br, broad. Signals due to NH and OH protons were located by 
deuterium exchange with D2O. Mass spectra were recorded on Agilent GC-MS 689-973. 
Chromatographic separations were performed on silica gel 60 for column chromatography (Merck 
70-230 mesh, or alternatively 15-40 mesh for flash chromatography). Purity ( 95%) of the 
pharmacologically tested compounds was established by HPLC and elemental analysis. Elemental 
analyses (C, H, N) were performed on Euro EA3000 analyzer (Eurovector, Milan, Italy) in the 
Analytical Laboratory Service of the Dipartimento di Farmacia - Scienze del Farmaco, University of 
Bari, and the results agreed to within ± 0.40% of the theoretical values.  
 
2.1 Synthesis 
2.1.1. General procedure for preparation of chloroalkyl carbamate derivatives 3a, 3b and 3e 
A solution of the appropriate chloroalkyl chloroformate (1.50 mmol) in dry DCM (3 ml) was added 
dropwise to a stirred solution of 1.37 mmol of compound 1·HCl (de Candia et al., 2009) and TEA 
(2.74 mmol) in dry DCM (10 ml). The mixture was stirred at room temperature overnight. Then, the 
precipitate was filtered, and the filtrate was evaporated in vacuum. The residue was dissolved in 50 
ml of chloroform, and the solution was sequentially washed with 3×20 ml of saturated aqueous 
NaHCO3, 1N HCl and brine, dried over anhydrous Na2SO4, filtered and evaporated in vacuum. The 
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crude product was purified by crystallization or by silica gel flash chromatography to afford the 
desired compound. 
 
2.1.1.1 Chloromethyl 4-[({3-[(4-fluorobenzyl)oxy]phenyl}amino)carbonyl]piperidine-1-
carboxylate, 3a. Compound 3a was prepared according to the general procedure from compound 
1·HCl (500 mg, 1.37 mmol) and chloromethyl chloroformate (0.13 ml, 1.50 mmol). The crude 
product was purified by crystallization from EtOH in 54% yield (310 mg) as a pale brown solid; mp 
137-138 °C. IR (cm-1): 3264, 1662, 1612, 1445, 1208, 1088, 838, 699. 1H NMR (CDCl3) δ 7.45 (s, 
br, 1H), 7.41-7.37 (m, 2H), 7.23 (d, J = 8.0, 1H), 7.18 (s, 1H), 7.06 (t, J = 9.0, 2H), 6.91 (d, J = 7.5, 
1H), 6.72 (dd, J = 8.0 and 2.0, 1H), 5.80 (d, J = 13, 2H), 5.01 (s, 2H), 4.28 (d, J = 13, 1H), 4.18 (d, J 
= 13, 1H), 2.99 (d, J = 13, 1H), 2.90 (d, J = 13, 1H), 2.50-2.35 (m, 1H), 2.00-1.90 (m, 2H), 1.85-1.70 
(m, 2H). 
 
2.1.1.2. 2-Chloroethyl 4-[({3-[(4-fluorobenzyl)oxy]phenyl}amino)carbonyl]piperidine-1-
carboxylate, 3b. Compound 3b was prepared according to the general procedure from compound 
1·HCl (500 mg, 1.37 mmol) and 2-chloroethyl chloroformate (0.15 ml, 1.56 mmol). The crude 
product was purified by crystallization from EtOH in 78% yield (466 mg) as a brown solid ; mp 132-
134 °C. IR (cm-1): 3230, 1660, 1605, 1445, 1205, 1078, 838, 696. 1H NMR (CDCl3) δ 7.46 (t, J = 2.0, 
1H), 7.43-7.36 (m, 2H), 7.25-7.18 (m, 2H), 7.10-7.02 (m, 2H), 6.92 (d, J = 8.0, 1H), 6.72 (dd, J = 8.0 
and 1.5, 1H), 5.01 (s, 2H), 4.34 (t, J = 6, 2H), 4.30-4.15 (m, 2H), 3.69 (t, J = 6.0, 2H), 3.00-2.85 (m, 
2H), 2.45-3.35 (m, 1H), 2.00-1.85 (m, 2H), 1.75-1.20 (m, 2H). 
 
2.1.1.3. Chloromethyl 4-[({3-[(3',5'-difluoro-1,1'-biphenyl-4-yl)methoxy]phenyl}amino)carbonyl] 
piperidine-1-carboxylate, 3e. Compound 3e was prepared was prepared according to the general 
procedure from compound 2·HCl (175 mg, 0.38 mmol) and chloromethyl chloroformate (0.1 ml, 1.14 
mmol). The crude product was purified by silica gel flash chromatography (eluent: Hex/EtOAc, 7:3 
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v/v) in 89% yield (175 mg) as an orange oil. IR (cm-1): 3333, 2928, 1728, 1660, 1610, 1442, 1206, 
1119, 1086, 989, 847, 783, 689. 1H NMR (DMSO-d6) δ 9.93 (s, 1H), 7.75 (d, J = 8.0, 2H), 7.52 (d, J 
= 8.0, 2H), 7.50-7.40 (m, 3H), 7.30-7.05 (m, 3H), 6.68 (dd, J = 8.0 and 1.5, 1H), 5.88 (d, J = 3.5, 1H), 
5.11 (s, 2H), 4.10-3.90 (m, 2H), 2.95 (t, J = 12, 2H), 2.89 (t, J = 12, 2H), 2.60-2.45 (m, 1H), 1.90-
1.70 (m, 2H), 1.60-1.40 (m, 2H). 
 
2.1.2. General procedure for preparation of halogenoalkyl carbamate derivatives 3c and 3d 
4-Nitrophenyl chloroformate (3.60 mmol) was added portionwise to a 0 °C cooled solution of the 
appropriate halogenoalkyl alcohol (3.60 mmol) and TEA (5.40 mmol) in dry THF (10 ml), and the 
mixture was stirred 3 h at 0 °C. Then, compound 1·HCl (3.60 mmol) and TEA (3.60 mmol) were 
added, and the mixture was stirred at room temperature overnight. The formed precipitate was 
filtered, and the filtrate evaporated in vacuum. The residue was dissolved in 50 ml of chloroform, and 
the solution was sequentially washed with 3×20 ml of saturated aqueous NaHCO3, 1N HCl and brine, 
dried over anhydrous Na2SO4, filtered and evaporated to dryness. The crude oil product was purified 
by silica gel flash chromatography to afford the desired compound. 
 
2.1.2.1. 3-Bromopropyl 4-[({3-[(4-fluorobenzyl)oxy]phenyl}amino)carbonyl]piperidine-1-
carboxylate, 3c. Compound 3c was prepared according to the general procedure from compound 
1·HCl (1.31 g, 3.60 mmol) and 3-bromo-1-propanol (0.32 ml, 3.60 mmol). The crude product was 
purified by silica gel flash chromatography (eluent: Hex/EtOAc, 4:6 v/v) in 50% yield (0.890 g) as a 
brown oil. IR (cm-1): 3230, 1656, 1600, 1448, 1210, 1068, 840, 700. 1H NMR (CDCl3) δ 7.48 (s, 1H), 
7.46-7.36 (m, 2H), 7.23-7.17 (m, 2H), 7.06 (t, J = 9.0, 2H), 6.91 (d, J = 7.0, 1H), 6.72 (dd, J = 8.0 and 
2.5, 1H), 5.02 (s, 2H), 4.23 (t, J = 6, 2H), 4.30-4.20 (m, 2H), 3.47 (t, J = 6.5, 2H), 2.95-2.80 (m, 2H), 
2.50-2.35 (m, 1H), 2.20 (t, J = 6.5, 2H), 2.00-1.87 (m, 2H), 1.85-1.70 (m, 2H). 
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2.1.2.2. 4-Chlorobutyl 4-[({3-[(4-fluorobenzyl)oxy]phenyl}amino)carbonyl]piperidine-1-
carboxylate, 3d. Compound 3d was prepared according to the general procedure from compound 
1·HCl (850 mg, 2.34 mmol) and 4-chloro-1-butanol (0.23 ml, 2.34 mmol). The crude product was 
purified by silica gel flash chromatography (eluent: Hex/EtOAc, 7:3 v/v) in 55% yield (570 mg) as a 
brown oil. IR (cm-1): 3227, 1650, 1600, 1445, 1208, 1080, 837, 696. 1H NMR (CDCl3) δ 7.45 (s, 1H), 
7.42-7.36 (m, 2H), 7.32-7.20 (m, 2H), 7.08 (dd, J = 8.5 and 2.0, 1H), 7.03 (d, J = 2.0, 1H), 6.91 (d, J 
= 7.0, 1H), 6.72 (d, J = 8.0, 1H), 5.01 (s, 2H), 4.40-4.00 (m, 4H), 3.80 (t, J = 6.0, 2H), 3.58 (t, J = 5.5, 
2H), 2.95-2.85 (m, 2H), 2.55-2.45 (m, 1H), 1.98-1.70 (m, 6H). 
 
2.1.3. General procedure for preparation of halogenoalkyl amide derivatives 4a and 4b 
A solution of the appropriate bromoacyl halide (2.10 mmol) in dry THF (2 ml) was added dropwise 
to a 0 °C cooled solution of compound 1·HCl (1.37 mmol) and TEA (2.74 mmol) in dry THF (20 
ml). The mixture was stirred at 0 °C for 1 h and at room temperature overnight. The precipitate was 
filtered, and the filtrate evaporated in vacuum. The residue was diluted with EtOAc (50 ml) and the 
organic phase was sequentially washed with 3×20 ml of saturated aqueous NaHCO3, 1N HCl and 
brine, dried over anhydrous Na2SO4, filtered and evaporated in vacuum. The crude product was 
purified by silica gel flash chromatography to afford the desired compound. 
 
2.1.3.1. 1-(Bromoacetyl)-N-{3-[(4-fluorobenzyl)oxy]phenyl}piperidine-4-carboxamide, 4a. 
Compound 4a was prepared according to the general procedure from compound 1·HCl (500 mg, 1.37 
mmol) and bromoacetyl bromide (0.18 ml, 2.10 mmol). The crude product was purified by silica gel 
flash chromatography (eluent: Hex/EtOAc, 1:9 v/v) in 55% yield (340 mg) as a brown oil. IR (cm-1): 
3233, 1652, 1605, 1443, 1198, 1080, 838, 696. 1H NMR (CDCl3) δ 7.43 (t, J = 2.0, 1H), 7.45-7.32 
(m, 2H), 7.25-7.18 (m, 2H), 7.08-7.00 (m, 2H), 6.90 (d, J = 8.0, 1H), 6.75 (dd, J = 8.0 and 1.5, 1H), 
5.00 (s, 2H), 4.30-4.15 (m, 2H), 3.20 (t, J = 6.0, 2H), 3.00-2.85 (m, 2H), 2.45-3.35 (m, 1H), 2.00-1.85 
(m, 2H), 1.75-1.20 (m, 2H). 
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2.1.3.2. 1-(Bromopropanoyl)-N-{3-[(4-fluorobenzyl)oxy]phenyl}piperidine-4-carboxamide, 4b. 
Compound 4b was prepared according to the general procedure from compound 1·HCl (500 mg, 1.37 
mmol) and 3-bromopropionyl chloride (0.20 ml, 2.10 mmol) in DCM (15 ml). The crude product was 
purified by silica gel flash chromatography (eluent: Hex/EtOAc, 1:9 v/v) in 64% yield (400 mg) as a 
brown solid; mp 164-165 °C. IR (cm-1): 3275, 1653, 1638, 1433, 1206, 1022, 838, 690. 1H NMR 
(CDCl3) δ 7.57 (s, br, 1H), 7.44 (s, 1H), 7.41-7.35 (m, 2H), 7.20 (t, J = 8.0, 1H), 7.05 (t, J = 8.0, 2H), 
6.93 (t, J = 8.0, 1H), 6.71 (dd, J = 8.0 and 2.0,1H), 5.00 (s, 2H), 4.60 (d, J = 13, 2H), 3.86 (d, J = 13, 
2H), 3.64 (t, J = 7.0, 2H), 3.12 (d, J = 12, 1H), 2.92 (t, J = 7.0, 2H), 2.73 (t, J = 13, 1H), 2.55-2.45 (m, 
1H), 2.00-1.90 (m, 2H), 1.85-1.65 (m, 2H). 
 
2.1.4. General procedure for preparation of nitric ester derivatives 5a-e and 6a-b 
A suspension of the appropriate alkyl halide intermediates (1.0 mmol) and AgNO3 (2.0 mmol) in dry 
ACN (10 ml) was heated at reflux until reaction completion (TLC monitoring). After cooling, the 
suspension was filtered on Celite, and pad was washed with ACN (50 ml). The combined filtrates 
were evaporated in vacuum and the residue was purified by silica gel flash chromatography and/or 
crystallization. 
 
2.1.4.1. (Nitrooxy)methyl 4-[({3-[(4-fluorobenzyl)oxy]phenyl}amino)carbonyl]piperidine-1-
carboxylate, 5a. Compound 5a was prepared according to the general procedure from 3a (400 mg, 
0.95 mmol) and AgNO3 (323 mg, 1.90 mmol). The crude product was purified by silica gel flash 
chromatography (eluent: Hex/EtOAc, 3:7 v/v) in 57% yield (240 mg) as a pale yellow solid, which 
was further purified by crystallization from EtOAc/Hex; mp 130-131 °C. IR (cm-1): 3262, 1732, 1358, 
1545, 1443, 1291, 1205, 1118, 951, 827. 1H NMR (DMSO-d6) δ 9.90 (s, 1H), 7.75 (d, J = 8.0, 2H), 
7.52 (d, J = 8.0, 2H), 7.47-7.40 (m, 4H), 7.28-7.05 (m, 3H), 6.68 (d, J = 8.0, 1H), 6.07 (s, 2H), 5.11 
(s, 2H), 3.98 (t, J = 13, 2H), 2.99-2.68 (m, 2H), 2.55-2.45 (m, 1H), 1.851.70 (m, 2H), 1.60-1.45 (m, 
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2H). MS (ESI) m/z 470 [M + Na]+. Anal. calcd. for C21H22FN3O7: C, 56.37; H, 4.96; N, 9.39%; found: 
C, 56.55; H, 4.99; N, 9.43%. 
 
2.1.4.2. 2-(Nitrooxy)ethyl 4-[({3-[(4-fluorobenzyl)oxy]phenyl}amino)carbonyl]piperidine-1-
carboxylate, 5b. Compound 5b was prepared according to the general procedure from 3b (500 mg, 
1.15 mmol) and AgNO3 (390 mg, 2.30 mmol). The crude product was purified by crystallization from 
EtOAc in 75% yield (400 mg) as a brown solid; mp 89-91 °C. IR (cm-1): 3430, 1635, 1442, 1384, 
1280, 1204, 1040, 860. 1H NMR (DMSO-d6) δ 9.90 (s, 1H), 7.47 (t, J = 8.5, 2H), 7.39 (s, 1H), 7.25-
7.00 (m, 4H), 6.66 (dd, J = 8.0 and 1.5, 1H), 5.02 (s, 2H), 4.76-4.70 (m, 2H), 4.32-4.25 (m, 2H), 4.05-
3.90 (m, 2H), 2.95-2.75 (m, 2H), 2.55-2.40 (m, 1H), 1.85-1.70 (m, 2H), 1.60-1.40 (m, 2H). MS (ESI) 
m/z 484 [M + Na]+. Anal. calcd. for C22H24FN3O7×H2O: C, 55.11; H, 5.47; N, 8.76%; found: C, 
55.41; H, 5.27; N, 8.74%. 
 
2.1.4.3. 3-(Nitrooxy)propyl 4-[({3-[(4-fluorobenzyl)oxy]phenyl}amino)carbonyl]piperidine-1-
carboxylate, 5c. Compound 5c was prepared according to the general procedure from 3c (845 mg, 
1.71 mmol) and AgNO3 (581 mg, 3.42 mmol). The crude product was purified by silica gel flash 
chromatography (eluent: Hex/EtOAc, 6:4 v/v) in 61% yield (500 mg) as a pale brown solid, which 
was further purified by crystallization from Hex/EtOAc; mp 91-93 °C. IR (cm-1): 3432, 1702, 1622, 
1436, 1279, 1207, 1037, 869. 1H NMR (DMSO-d6) δ 9.89 (s, 1H), 7.47 (t, J = 8.5, 2H), 7.38 (d, J = 
2.0, 1H), 7.30-7.00 (m, 4H), 6.66 (dd, J = 7.5 and 1.5, 1H), 5.02 (s, 2H), 4.59 (t, J = 6.5, 2H), 4.07 (t, 
J = 6.5, 2H), 4.00 (t, J = 13, 2H), 2.90-2.75 (m, 2H), 2.55-2.45 (m, 1H), 1.99 (quintet, J = 6.5, 2H), 
1.85-1.70 (m, 2H), 1.60-1.40 (m, 2H). MS (ESI) m/z 498 [M + Na]+. Anal. calcd. for C23H26FN3O7: 
C, 58.10; H, 5.51; N, 8.84%; found: C, 58.34; H, 5.56; N, 8.58%. 
 
2.1.4.4. 4-(Nitrooxy)butyl 4-[({3-[(4-fluorobenzyl)oxy]phenyl}amino)carbonyl]piperidine-1-
carboxylate, 5d. Compound 5d was synthesized according to the general procedure from 3d (400 mg, 
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0.89 mmol) and AgNO3 (303 mg, 1.78 mmol). The crude product was purified by silica gel flash 
chromatography (eluent: Hex/EtOAc, 7:3 v/v) in 71% yield (310 mg) as a brown solid, which was 
further purified by crystallization from Hex/EtOAc; mp 117-115 °C. IR (cm-1): 3432, 2954, 1716, 
1661, 1612, 1523, 1431, 1201, 1155, 1040, 865, 825, 781, 742, 689. 1H NMR (CDCl3) δ 7.45 (s, 1H), 
7.42-7.36 (m, 2H), 7.24-7.15 (m, 2H), 7.11-7.00 (m, 2H), 6.92 (d, J = 7, 1H), 6.72 (dd, J = 8.0 and 
2.5, 1H), 5.02 (s, 2H), 4.50-4.20 (m, 2H), 4.13 (t, J = 6.0, 2H), 3.58 (t, J = 6.0, 2H), 2.88 (d, J = 12, 
1H), 2.84 (d, J = 12, 1H), 2.50-2.30 (m, 1H), 2.00-1.65 (m, 8H). MS (ESI) m/z 512 [M + Na]+. Anal. 
calcd. for C24H28FN3O7: C, 58.89; H, 5.77; N, 8.58%; found: C, 59.02; H, 5.87; N, 8.58%. 
 
2.1.4.5. (Nitrooxy)methyl 4-[({3-[(3',5'-difluoro-1,1'-biphenyl-4-yl)methoxy]phenyl}amino) 
carbonyl]piperidine-1-carboxylate, 5e. Compound 5e was prepared according to the general 
procedure from 3e (170 mg, 0.33 mmol) and AgNO3 (70 mg, 0.39 mmol). The crude product was 
purified by silica gel flash chromatography (eluent: Hex/EtOAc, 7:3 v/v), in 65% yield (116 mg) as 
a pale yellow solid, which was further purified by crystallization from Hex/EtOAc; mp 130-131 °C. 
IR (cm-1): 3200, 2930, 1732, 1658, 1598, 1545, 1443, 1384, 1291, 1205, 1118, 1086, 951, 827, 689. 
1H NMR (DMSO-d6) δ 9.92 (s, 1H), 7.75 (d, J = 8.0, 2H), 7.52 (d, J = 8.0, 2H), 7.48-7.40 (m, 3H), 
7.30-7.05 (m, 3H), 6.68 (dd, J = 8.0 and 1.5, 1H), 6.07 (s, 2H), 5.11 (s, 2H), 4.05-3.95 (m, 2H), 2.94 
(t, J = 12, 1H), 2.87 (t, J = 12, 1H), 2.60-2.50 (m, 1H), 1.90-1.70 (m, 2H), 1.60-1.40 (m, 2H). Anal. 
calcd. for C27H25F2N3O7: C, 59.89; H, 4.65; N, 7.76%; found: C, 60.02; H, 4.77; N, 7.90%. 
 
2.1.4.6. 2-{4-[({3-[(4-Fluorobenzyl)oxy]phenyl}amino)carbonyl]piperidin-1-yl}-2-oxoethyl nitrate, 
6a. Compound 6a was prepared according to the general procedure from 4a (230 mg, 0.5 mmol) and 
AgNO3 (170 mg, 1.0 mmol). The crude product was purified by silica gel flash chromatography 
(eluent: MeOH/EtOAc, 5:95 v/v) in 56% yield (120 mg) as a white solid, which was further purified 
by crystallization from EtOAc; mp 135-136 °C. IR (cm-1): 3306, 1651, 1552, 1446, 1376, 1291, 1207, 
1037, 955, 856, 798, 785, 689. 1H NMR (DMSO-d6) δ 9.92 (s, 1H), 7.50-7.43 (m, 2H), 7.39 (s, 1H), 
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7.20 (t, J = 9.0, 2H), 7.18-7.05 (m, 2H), 6.66 (dd, J = 7.0 and 1.0, 1H), 5.39 (q, J = 13, 2H), 5.02 (s, 
2H), 4.80 (s, 2H), 4.30 (d, J = 13, 1H), 3.73 (d, J = 13, 1H), 3.07 (t, J = 12, 1H), 2.69 (t, J = 12, 1H), 
2.65-2.50 (m, 1H), 1.80 (d, J = 11, 2H), 1.75-1.55 (m, 1H), 1.55-1.35 (m, 1H). MS (ESI) m/z 478 [M 
+ Na]+. Anal. calcd. for C22H24FN3O7×H2O: C, 55.11; H, 5.47; N, 8.76%; found: C, 55.41; H, 5.27; 
N, 8.74%. 
 
2.1.4.7. 2-{4-[({3-[(4-Fluorobenzyl)oxy]phenyl}amino)carbonyl]piperidin-1-yl}-3-oxopropyl 
nitrate, 6b. Compound 6b was prepared according to the general procedure from 4b (500 mg, 1.10 
mmol) and AgNO3 (372 mg, 2.20 mmol). The crude product was purified by crystallization from 
EtOAc in 62% yield (300 mg) as a white solid; mp 154-156 °C. IR (cm-1): 3330, 1683, 1633, 1551, 
1381, 1285, 1200, 1159, 1041, 974, 857, 783, 690. 1H NMR (DMSO-d6) δ 9.86 (s, 1H), 7.50-7.45 
(m, 2H), 7.38 (s, 1H), 7.19 (t, J = 7.0, 2H), 7.15-7.05 (m, 2H), 6.66 (dd, J = 8.0 and 1.5, 1H), 5.02 (s, 
2H), 4.73 (t, J = 6.0, 2H), 4.38 (d, J = 13, 1H), 3.87 (d, J = 13, 1H), 3.03 (t, J = 12, 1H), 2.95-2.84 (m, 
2H), 2.79-2.50 (m, 2H), 1.79 (d, J = 13, 2H), 1.70-1.55 (m, 1H), 1.55-1.35 (m, 1H). MS (ESI) m/z 
468 [M + Na]+. Anal. calcd. for C22H24FN3O7×H2O: C, 55.11; H, 5.47; N, 8.76%; found: C, 55.41; 
H, 5.27; N, 8.74%. 
 
2.1.5. Preparation of the nitric ester derivative 9 
Compound 9 was synthesized through three main steps, starting with the preparation t-Boc-protected 
2-(methylamino)ethanol, used in the first step, through the following procedure. A solution of Boc2O 
(5.80 g, 26.6 mmol) in dry EtOAc (10 ml) was added dropwise to a 0 °C cooled solution of 2-
(methylamino)ethanol (2.14 ml, 26.6 mmol) in dry EtOAc (9 ml). The mixture was stirred at room 
temperature for 2 h, and then concentrated under reduced pressure. The oil residue was partitioned 
between EtOAc (100 ml) and water (300 ml), and the collected organic phases dried over anhydrous 
Na2SO4, filtered and evaporated in vacuum to furnish t-butyl 2-hydroxyethyl(methyl)carbamate in 
78% yield (3.66 g) of as a colorless oil. IR (liquid film, cm-1): 3444, 2977, 1673, 1394, 1225, 1156, 
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1074, 877, 774. 1H NMR (CDCl3) δ 3.72 -3.80 (m 3H), 3.40 (t, J = 5.0, 2H), 2.92 (s, 3H), 1.47 (s, 
9H). 
 
2.1.5.1. 2-(Methyl)amino]ethyl 4-[({3-[(4-fluorobenzyl)oxy]phenyl}amino)carbonyl] piperidine-1-
carboxylate, 7. 4-Nitrophenyl chloroformate (498 mg, 2.47 mmol) was added portionwise to a 0 °C 
cooled solution of t-butyl 2-hydroxyethyl(methyl)carbamate (433 mg, 2.47 mmol) and TEA (0.86 ml, 
6.18 mmol) in dry THF (10 ml), and the mixture was stirred at 0 °C for 3 h. Then, compound 1·HCl 
(900 mg, 2.47 mmol) was added, and the mixture stirred overnight at room temperature. The formed 
precipitate was filtered, and the filtrate evaporated to dryness, leaving a solid residue which was 
dissolved in EtOAc (50 ml). The EtOAc solution was sequentially washed with 2×20 ml of saturated 
aqueous NaHCO3, 1N HCl and brine, dried over anhydrous Na2SO4, filtered and evaporated in 
vacuum. The crude residue which was purified by silica gel flash chromatography (eluent: Hex/ethyl 
acetate, 4:6 v/v), providing t-Boc-protected compound 7 as a pale yellow oil in 50% yield (645 mg). 
IR (cm-1): 3435, 2931, 1697, 1608, 1384, 1204, 1155, 864, 827, 770. 1H NMR (CDCl3) δ 7.45 (t, J = 
2.0, 1H), 7.42-7.36 (m, 2H), 7.22-7.16 (m, 2H), 7.06 (dt, J = 8.5 and 2.0, 2H), 6.92 (dd, J = 8.0 and 
1.5, 1H), 6.72 (dd, J = 8.0 and 2.0, 1H), 5.01 (s, 2H), 4.30-4.15 (m, 4H), 3.55-3.45 (m, 2H), 2.95-2.75 
(m, 5H), 2.50-2.35 (m, 1H), 1.95-1.85 (m, 2H), 1.85-1.60 (m, 2H), 1.45 (s, 9H). 
A mixture of t-Boc-protected 7 (645 mg, 1.24 mmol) and redistilled TFA (0.55 ml, 6.18 mmol) in 
DCM (20 ml) was stirred at room temperature until reaction completion (TLC monitoring), to produce 
compound 7 as TFA salt in quantitative yield (535 mg) as a pale brown oil. IR (cm-1): 3247, 2945, 
1708, 1651, 1606, 1434, 1205, 1009, 837, 721. 1H NMR (DMSO-d6) δ 9.92 (s, 2H), 8.53 (s, br, 1H), 
7.48-7.43 (m, 2H), 7.38 (s, 1H), 7.20 (t, J = 8.0, 1H), 7.12-7.00 (m, 2H), 6.67 (dd, J = 8.0 and 1.5, 
2H), 5.02 (s, 2H), 4.19 (t, J = 5.0, 2H), 4.18-4.00 (m, 2H), 3.18 (t, J = 5.0, 2H), 2.90-2.70 (m, 3H), 
2.60 (t, J = 5.0, 2H), 2.55-2.45 (m, 1H), 1.85-1.65 (m, 2H), 1.60-1.40 (m, 2H). 
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2.1.5.2. 2-[(Bromoacetyl)(methyl)amino]ethyl 4-[({3-[(4-fluorobenzyl)oxy]phenyl}amino)carbonyl] 
piperidine-1-carboxylate, 8. A solution of bromoacetyl bromide (0.17 ml, 1.93 mmol) in dry DCM 
(3 ml) was added dropwise to a 0 °C cooled suspension of 7·TFA (750 mg, 1.75 mmol) and TEA (0.5 
ml, 3.50 mmol) in dry DCM (8 ml). The mixture was stirred overnight at room temperature, then was 
filtered and the filtrate diluted with DCM (20 ml). The organic phase was washed with 2×20 ml of 
saturated aqueous NaHCO3, 1N HCl and brine, dried over anhydrous Na2SO4, filtered and evaporated 
to dryness, to give the crude product (407 mg, 48% yield), which was used without further purification 
in the subsequent reaction. MS (ESI) m/z: 550 [M + H]+. IR (cm-1): 3321, 2922, 1693, 1646, 1606, 
1440, 1204, 1125, 1036, 873, 768. 
 
2.1.5.3. 2-{Methyl[(nitrooxy)acetyl]amino}ethyl 4-[({3-[(4-fluorobenzyl)oxy]phenyl}amino) 
carbonyl]piperidine-1-carboxylate, 9. Compound 9 was prepared, according to the above described 
procedure from 8 (350 mg, 0.64 mmol) and AgNO3 (162 mg, 0.95 mmol). The crude product was 
purified by crystallization from EtOAc in 55% yield (195 mg) as a brown solid; mp 120-121 °C. IR 
(cm-1): 3433, 1650, 1541, 1439, 1384, 1286, 1045, 852. 1H NMR (DMSO-d6) δ 9.87 (s, 1H), 7.50-
7.40 (m, 2H), 7.39 (s, 1H), 7.25-7.14 (m, 3H), 7.09 (d, J = 8.5, 1H), 6.66 (dd, J = 8.0 and 1.5, 1H), 
5.34 (s, 2H), 4.22-4.10 (m, 2H), 4.07 (t, J = 5.0, 2H), 4.05-3.95 (m, 2H), 3.60-3.50 (m, 2H), 2.98 (s, 
3H), 2.55-2.45 (m, 1H), 1.65-1.45 (m, 2H), 1.55-1.40 (m, 2H). MS (ESI) m/z 555 [M + Na]+. Anal. 
calcd. for C25H29FN4O8: C, 56.39; H, 5.49; N, 10.52%; found: C, 56.58; H, 5.66; N, 10.68%. 
 
2.1.6. General procedure for preparation of hydroxyalkyl carbamate derivatives 12a and 12b 
A solution of benzoyl chloride (1.7 ml, 14.7 mmol) in dry THF (10 ml) was added dropwise to a 0 
°C cooled solution of ethylene glycol or 1,3-propanediol (16.1 mmol) for 10a or 10b, respectively, 
and TEA (4 ml, 29.4 mmol) in dry THF (20 ml). The mixture was stirred at room temperature 
overnight. The formed precipitate was filtered, the filtrate was evaporated to dryness and the solid 
residue was dissolved in EtOAc (50 ml). The organic phase was sequentially washed with 3×20 ml 
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of saturated aqueous NaHCO3, 1N HCl and brine, dried over anhydrous Na2SO4, filtered and 
evaporated in vacuum, to provide a residue containing the desired crude products 10a and 10b (65% 
GC yield), which were used in the subsequent reactions without further purification. 
A solution of 4-nitrophenyl chloroformate (950 mg, 4.70 mmol) in dry THF (5 ml) was added 
dropwise to a 0 °C cooled solution of crude product 10a or 10b (4.51 mmol) in dry THF (10 ml) and 
TEA (1.9 ml, 13.5 mmol), and the mixture was stirred at 0 °C for 2 h. Then, compound 1·HCl (1.26 
g, 3.86 mmol) was added, and the mixture was stirred at room temperature overnight. The formed 
precipitate was filtered, the solvent was evaporated in vacuum and the solid  residue was dissolved in 
EtOAc (50 ml). The organic phase was sequentially washed with 2×20 ml of saturated aqueous 
NaHCO3 and brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. 
The crude products 11a and 11b were purified by silica gel flash chromatography. 
A mixture of 11a or 11b (1.20 mmol) in THF (10 ml), MeOH (2 ml) and aqueous 2N NaOH solution 
(3 ml) was stirred at room temperature for 6h, until reaction completion (TLC monitoring). The 
solution was then concentration under reduced pressure, and the oil residue was dissolved in EtOAc 
(50 ml) and partitioned with brine. The organic phase was dried over anhydrous Na2SO4, filtered and 
evaporated to dryness. The crude product was purified by crystallization or silica gel flash 
chromatography. 
 
2.1.6.1. 2-(Benzoyloxy)ethyl 4-[({3-[(4-fluorobenzyl)oxy]phenyl}amino)carbonyl]piperidine-1-
carboxylate, 11a. Compound 11a was prepared was prepared according to the general procedure from 
crude 2-hydroxyethyl benzoate 10a (750 mg, 4.51 mmol) and compound 1·HCl (1.26 g, 3.86 mmol). 
The crude product was purified by silica gel flash chromatography (eluent: Hex/EtOAc, 1:1 v/v) in 
45% yield (1.06 g) as a pale brown solid, which was crystallized from Hex/EtOAc; mp 142-144 °C. 
IR (cm-1): 3269, 1729, 1698, 1647, 1605, 1276, 1208, 837, 707. 1H NMR (CDCl3) δ 8.08-8.02 (m, 
2H), 7.56 (t, J = 7.5, 1H), 7.49-7.36 (m, 5H), 7.21 (t, J = 8.0, 1H), 7.16 (s, br, 1H), 7.06 (t, J = 9.0, 
2H), 6.92 (dd, J = 8.0 and 1.5, 1H), 6.72 (dd, J = 8.0 and 1.5, 1H), 5.01 (s, 2H), 4.58-4.53 (m, 2H), 
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4.46-4.41 (m, 2H), 4.30-4.15 (m, 2H), 2.89 (d, J = 12, 1H), 2.85 (d, J = 12, 1H), 2.45-2.35 (m, 1H), 
2.00-1.85 (m, 2H), 1.85-1.65 (m, 2H). 
 
2.1.6.2. 3-(Benzoyloxy)propyl 4-[({3-[(4-fluorobenzyl)oxy]phenyl}amino)carbonyl]piperidine-1-
carboxylate, 11b. Compound 11b was prepared was prepared according to the general procedure from 
crude 3-hydroxypropyl benzoate (500 mg, 2.68 mmol) and compound 1·HCl (750 mg, 2.28 mmol). 
The crude product was purified by silica gel flash chromatography (eluent: Hex/EtOAc, 1:1 v/v) in 
55% yield (785 mg) as a white solid, which was crystallized from Hex/EtOAc; mp 135-137 °C. IR 
(cm-1): 3290, 1715, 1703, 1661, 1278, 1202, 1122, 822, 709. 1H NMR (CDCl3) δ 8.03 (d, J = 7.0, 
2H), 7.56 (t, J = 7.5, 1H), 7.48-7.35 (m, 5H), 7.23 (s, br, 1H), 7.19 (d, J = 8.0, 1H), 7.06 (t, J = 9.0, 
2H), 6.93 (dd, J = 8.0 and 1.0, 1H), 6.71 (dd, J = 8.0 and 2.0, 1H), 5.00 (s, 2H), 4.43 (t, J = 6.0, 2H), 
4.28 (t, J = 6.0, 2H), 4.27 (m, 2H), 2.85 (d, J = 12, 1H), 2.81 (d, J = 12, 1H), 2.45-2.30 (m, 1H), 2.14 
(quintet, J = 6.0, 2H), 1.95-1.75 (m, 2H), 1.73-1.60 (m, 2H). 
 
2.1.6.3. 2-Hydroxyethyl 4-[({3-[(4-fluorobenzyl)oxy]phenyl}amino)carbonyl]piperidine-1-
carboxylate, 12a. Compound 12a was prepared was prepared according to the general procedure from 
11a (635 mg, 1.22 mmol). The crude product was purified by crystallization from EtOH, with addition 
of few drops of water, in 55% yield (260 mg) as a pale yellow solid; mp 174-175 °C. IR (cm-1): 3508, 
3250, 2922, 2867, 1703, 1654, 1605, 1434, 1229, 1204, 1072, 839, 687. 1H NMR (DMSO-d6) δ 9.90 
(s, 1H), 7.50-7.43 (m, 2H), 7.39 (t, J = 2.0, 1H), 7.25-7.05 (m, 4H), 6.66 (dd, J = 8.5 and 1.5, 1H), 
5.02 (s, 2H), 4.77 (t, J = 5.0, 1H), 4.03 (d, J = 12.5, 2H), 3.98 (t, J = 5.0, 2H), 3.54 (q, J = 5.0, 2H), 
2.95-2.85 (m, 2H), 2.50-2.40 (m, 1H), 1.80-1.75 (m, 2H), 1.55-1.40 (m, 2H). Anal. calcd. for 
C22H25FN2O5: C, 63.45; H, 6.05; N, 6.73%; found: C, 63.63; H, 6.12; N, 6.72%. 
 
2.1.6.4. 3-Hydroxypropyl 4-[({3-[(4-fluorobenzyl)oxy]phenyl}amino)carbonyl]piperidine-1-
carboxylate, 12b. Compound 12b was prepared according to the general procedure from 11b (365 
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mg, 0.68 mmol). The crude product was purified by silica gel flash chromatography (eluent: 
Hex/EtOAc, 3:7 v/v) in 92% yield (270 mg) as a yellow oil. IR (cm-1): 3416, 3316, 2951, 2870, 1675, 
1606, 1539, 1437, 1225, 1155, 1046, 955, 865, 826, 760. 1H NMR (CDCl3) δ 7.45 (s, 1H), 7.43-7.37 
(m, 2H), 7.21 (t, J = 8.0, 1H), 7.17 (s, br, 1H), 7.06 (t, J = 9.0, 2H), 6.92 (d, J = 8.5, 1H), 6.72 (dd, J 
= 8.0 and 2.5, 1H), 5.02 (s, 2H), 4.28 (t, J = 6.0, 2H), 4.25-4.10 (m, 4H), 2.95-2.80 (m, 2H), 2.50-
2.35 (m, 1H), 2.00-1.55 (m, 7H).  
 
2.1.7. Preparation of benzyl nitrate derivative 15 
Compound 15 was prepared through a two-step synthesis, starting from the already reported 1-t-Boc-
protected N-(3-hydroxyphenyl)piperidine-4-carboxamide 13 (de Candia et al., 2009). 
 
2.1.7.1. Tert-butyl-4-{[(3-{[4-(bromomethyl)benzyl]oxy}phenyl)amino]carbonyl}piperidine-1-
carboxylate, 14. ,’-Dibromo-p-xylene (298 mg, 1.13 mmol) and anhydrous K2CO3 (195 mg, 1.41 
mmol) were added to a solution of compound 13 (300 mg, 0.94 mmol) in Me2CO (15 ml). The mixture 
was refluxed until disappearance of 13 (TLC monitoring). After cooling and removal of the reaction 
solvent, the residue was partitioned between EtOAc (50 ml) and brine (50 ml). The organic phase 
was dried over anhydrous Na2SO4, filtered and evaporated to dryness. The crude product was purified 
by silica gel flash chromatography (Hex/EtOAc, 1:1 v/v) in 60% yield (285 mg) as a brown oil. IR 
(cm-1): 3300, 2973, 2929, 2851, 1694, 1651, 1584, 1421, 1286, 1213, 1163, 1041, 781. 1H NMR 
(CDCl3) δ 7.50-7.40 (m, 5H), 7.11 (s, 1H), 6.92 (d, J = 6.5, 1H), 6.72 (d, J = 6.5, 1H), 5.43 (s, 2H), 
5.08 (s, 2H), 4.25-4.15 (m, 2H) 2.79 (t, J = 12, 2H), 2.45-2.30 (m, 1H), 1.95-1.85 (m, 2H), 1.80-1.60 
(m, 2H), 1.46 (s, 9H). 
 
2.1.7.2. 4-({3-[(Piperidin-4-ylcarbonyl)amino]phenoxy}methyl)benzyl nitrate hydrochloride, 15. 
Compound 15 was synthesized according to the general procedure, as described for 5a, from 
compound 14 (350 mg, 0.70 mmol) and AgNO3 (233 mg, 1.37 mmol). The crude N-Boc derivative 
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of compound 15 was purified by silica gel flash chromatography (Hex/EtOAc, 1:1 v/v) in 65% yield 
(220 mg) as a brown oil. IR (cm-1): 3300, 2973, 2930, 2851, 1698, 1661, 1631, 1550, 1421, 1280, 
1214, 1163, 1042, 957, 867, 856, 774, 690. 1H NMR (CDCl3) δ 7.48 (s, 1H), 7.46 (d, J = 8.0, 2H), 
7.40 (d, J = 8.0, 2H), 7.21 (t, J = 8.0, 1H), 7.15 (s, br, 1H), 6.92 (d, J = 7.0, 1H), 6.71 (dd, J = 8.0 and 
2.0, 1H), 5.43 (s, 2H), 5.08 (s, 2H), 4.25-4.10 (m, 2H), 2.78 (t, J = 12, 2H), 2.43-2.30 (m, 1H), 1.95-
1.85 (m, 2H), 1.80-1.65 (m, 2H), 1.46 (s, 9H). 
A 1.25 M HCl methanolic solution (2.0 ml, 2.25 mmol) was added to a solution of N-Boc-protected 
15 (220 mg, 0.45 mmol) in MeOH (20 ml), and the mixture was stirred at room temperature until 
reaction completion (TLC monitoring). After solvent evaporation in vacuum and trituration of the 
residue with abs. EtOH, the hydrochloride salt of 15 was obtained in quantitative yield (175 mg) as a 
pale brown solid, which was crystallized from EtOAc/EtOH; mp 102-104 °C. IR (cm-1): 3399, 2925, 
2800, 2709, 1692, 1615, 1544, 1385, 1284, 1208, 1162, 1121, 892, 873. 1H NMR (CDCl3) δ 10.06 
(s, 1H), 8.75 (s, br, 1H), 8.47 (s, br, 1H), 7.47 (s, 4H), 7.39 (d, J = 2.0, 1H), 7.18 (t, J = 8.0, 1H), 7.11 
(d, J = 8.0, 1H), 6.68 (dd, J = 8.0 and 1.5, 1H), 5.56 (s, 2H), 5.08 (s, 2H), 3.97 (d, J = 12.6, 1H), 3.32 
(d, J = 12.6, 1H), 2.88 (t, J = 12.6, 2H), 2.65-2.5 (m, 1H), 2.00-1.85 (m, 2H), 1.85-1.60 (m, 2H). MS 
(ESI) m/z 386 [M + H]+. Anal. Calcd. for C24H28FN3O7: C, 58.89; H, 5.77; N, 8.58%; found: C, 59.02; 
H, 5.87; N, 8.58%. 
 
2.3 Vasodilator activity 
Male Wistar rats were obtained from Harlan Laboratories (San Pietro al Natisone, Italy) and 
individually housed at constant room temperature (25  1 °C) and humidity (60  5 %), with an 
artificial 12:12 h light/dark cycle. Thoracic aortas were isolated from rats weighing 180-200 g. As 
few animals as possible were used. The purposes and the protocols of our studies have been approved 
by Ministero della Salute (Rome, Italy). All the procedures were performed in accordance with the 
Ethical Animal Committee of the University of Turin (Italy). 
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The endothelium was removed and the vessels were helically cut: four to six strips were obtained 
from each aorta. The tissues were mounted under 1.0 g tension in organ baths containing 30 ml of 
Krebs-bicarbonate buffer with the following composition (mM): NaCl 111.2, KCl 5.0, CaCl2 2.5, 
MgSO4 1.2, KH2PO4 1.0, NaHCO3 12.0, glucose 11.1, maintained at 37 °C and gassed with 95% O2-
5% CO2 (pH 7.4). The aorta strips were allowed to equilibrate for 120 min and then contracted with 
1 M L-phenylephrine. When the response to the agonist reached a plateau, cumulative concentrations 
of the test compound were added. Results are expressed as EC50 values; data are the mean  SEM of 
at least three experiments. The effects of 1 M ODQ on relaxation were evaluated in separate series 
of experiments in which it was added to the organ bath 5 min before contraction. Responses were 
recorded by an isometric transducer connected to the MacLab System PowerLab. Addition of the 
drug vehicle (1% DMSO) had no appreciable effect on contraction level. 
 
2.4 Inhibition of platelet aggregation 
Human blood was obtained from healthy volunteers (25-45 years of age), who had not ingested any 
platelet inhibitory drug for at least one week prior to donation. All subjects provided informed 
consent, and were treated according to Helsinki protocol for biomedical experimentation. 
Blood and blood products were handled in plastic ware, whereas siliconized glass cuvettes and stir 
bars were used in the aggregation assay. Platelet rich plasma (PRP) was prepared by centrifugation 
of citrated blood at 200×g for 20 min. The transmittance of PPP was taken as 100% aggregation. PRP 
(500 μl) was added into the aggregometer (Chrono-log 4902D) cuvettes and preincubated at 37 °C 
for 15 min with the tested compounds (final concentrations in the PRP solutions ranging from 10 μM 
to 300 µM) or with vehicle (to eliminate the effect of the solvent on the aggregation and release 
reaction of platelets; the final concentration of DMSO was fixed at 0.5%, v/v). Then, adenosine 5’-
diphosphate (ADP, 5 μM final concentration), or collagen at submaximal concentration (0.8-1.5 
g/ml) were added to the incubated sample and aggregation was recorded as increased light 
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transmission under continuous stirring (1000 rpm) at 37 °C for 10 min after addition of the 
aggregation inducer. The antiaggregatory activity of the tested compounds is expressed as percent 
inhibition of platelet aggregation compared with vehicle control samples. For most of the active 
compounds, IC50 values (i.e., the concentration effecting 50% inhibition of aggregation), was 
calculated by nonlinear regression analysis (r2 > 0.80); alternatively, percent inhibition at maximal 
concentration tested (300 M) is reported. The number of experiments was 3-5 for IC50 values, and 
3 for determination of % inhibition. 
 
2.3 Hydrolysis studies 
2.3.1 Hydrolysis in aqueous solutions. To 0.25 ml of a 10 mM stock solution of the compound in 
ACN, 1.75 ml of ACN and aqueous buffer solution (0.01 M HCl or 0.04 M phosphate buffer pH 7.4 
in 0.15 M KCl) were added to give a final volume of 10 ml. The solution at the final concentration of 
200 M was thermostated at 37 ± 0.5 °C. 
At appropriate time intervals, samples were withdrawn and analyzed by HPLC using 1260 Infinity 
Quaternary LC system (Agilent Technologies, Milan, Italy) equipped with autosampler, photodiode 
array detector and evaporative light scattering detector, and controlled by Lab Advisory software. A 
Phenomenex Kinetex C18 column 5 µm (150  3.0 mm i.d.) was used as the stationary phase; the 
analytes were eluted with a 23 min gradient from mobile phase A (65% v/v 20 mM ammonium 
formate aqueous solution in ACN) to mobile phase B (35% v/v 20 mM ammonium formate aqueous 
solution in ACN) at a constant flow rate of 0.5 ml/min; injection volume: 10 μl. 
Pseudo-first-order rate constants (kobs) for the hydrolysis of the compounds were calculated from the 
slopes of the linear plots of log (% remaining compound) against time. Each kinetic experiment was 
performed in triplicate. 
 
2.3.2 Stability in human serum. To 1.47 ml of human serum (lyophilized and reconstituted with 4 ml 
of deionized water), preheated at 37 ± 0.5 °C, 30 l of a 10 mM stock solution of each compound in 
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ACN were added and the solution was incubated at 37 ± 0.5 °C (final compound concentration 200 
µM). Aliquots (100 l) of the serum solution were taken at various times and deproteinized by mixing 
with 500 l of cold MeOH. The suspension was vortexed 1 min, centrifuged 10 min at 4350 rpm, and 
10 l of the supernatant were analyzed by HPLC as described above. The % amounts of the remaining 
intact compound were plotted against the incubation time. 
 
3. Results and discussion 
3.1 Chemistry 
The nitrooxy (ONO2)-containing compounds of compounds 1 and 2 were synthesized as outlined in 
Scheme 1. Compound 1·HCl was reacted with chloromethyl- and 2-chloroethyl chloroformate, in the 
presence of triethylamine (TEA), to provide chloromethyl- and chloroethyl carbamate derivatives 3a 
and 3b, respectively, which were then transformed into the corresponding (ONO2)methyl (5a) and 
(ONO2)ethyl (5b) derivatives by treatment with AgNO3 in acetonitrile (ACN) at reflux. Compound 
5e, i.e., the (ONO2)methyl carbamate of 2, was prepared using a similar procedure. Conversely, the 
synthesis of the intermediate bromopropyl (3c) and chlorobutyl (3d) carbamates was accomplished 
by activating 3-bromopropanol and 4-chlorobutanol as carbonates, by reaction with 4-nitrophenyl 
chloroformate, and subsequent aminolysis by 1. 
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Scheme 1. Synthesis of (ONO2)alkyl carbamate (A) and amide (B) derivatives of 3-substituted-
benzyloxy isonipecotanilides 1 and 2. Reagents and conditions: (i) a) ClCOOCH2Cl (for 3a and 3e), 
ClCOOCH2CH2Cl (for 3b), TEA, dry DCM, r.t., overnight, 54-78%; b) 4-nitrophenylchloroformate, 
TEA, Br(CH2)3OH (for 3c), Cl(CH2)4OH (for 3d), dry THF, 0 °C, 3 h, then 1, r.t., overnight, 50-55%. 
(ii) BrCH2COBr (for 4a), BrCH2CH2COBr (for 4b), TEA, dry THF, 0 °C, 1 h, then r.t., overnight, 
55-64%. (iii) AgNO3, CH3CN, reflux, 16-20 h, 55-75%. 
 
 
N-t-Boc-N’-methyl-2-aminoethanol was used to prepare the intermediate product 7, which after t-
Boc-deprotection and subsequent reaction with bromoacetyl bromide yielded compound 8, which 
was finally refluxed with AgNO3 in ACN to give the corresponding (ONO2)-substituted compound 
9. The (ONO2)-containing amide derivatives 6a,b were synthesized by reacting compound 1 with the 
appropriate bromoacyl bromides and subsequent nitrooxylation of the intermediate bromides 4a,b 
(Scheme 2). 
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Scheme 2. Synthesis of the (ONO2)-containing compound 9. Reagents and conditions: (i) 4-
nitrophenylchloroformate, TEA, dry THF, 0 °C, 3 h, then 1, r.t., overnight; TFA, DCM, r.t., 50%. (ii) 
BrCH2COBr, TEA, dry DCM, r.t., overnight, 48%. (iii) AgNO3, CH3CN, reflux, 16-20 h, 55-75%. 
 
 
To prove the effectiveness of our (ONO2)-containing derivatives as NO-releasing agents, the ethyl 
and propyl alcohols 12a and 12b, as hypothetical de-nitrated metabolites arising from 
biotransformation pathways involving hydrolytic cleavage of the nitric ester functions in 5b and 5c, 
respectively, were synthesized as outlined in Scheme 3. The mono benzoate esters 10a-b, once 
activated as carbonates by reaction with 4-nitrophenyl chloroformate, were transformed through 
aminolysis by 1 into the ester products 11a,b, which were then hydrolyzed in basic conditions to 
provide the respective hydroxyl derivatives 12a,b. 
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Scheme 3. Synthesis of hydroxyalkyl carbamate derivatives of 4-fluorobenzyloxy isonipecotanilide 
1. Reagents and conditions: (i) Benzoyl chloride, TEA, dry THF, r.t., overnight, 55-65%; (ii) 4-
nitrophenyl chloroformate, TEA, dry THF, r.t., 3 h; then 1, r.t., overnight, 45-55%; (iii) 2N NaOH, 
THF/MeOH 5:1 v/v, r.t., 12-16 h, 55-92%. 
 
 
Finally, the benzyl nitrate derivative 15 was synthesized as outlined in Scheme 4. Monobenzylation 
of the phenol OH in compound 13 (de Candia et al., 2009) by reaction with ,’-dibromo-p-xylene 
furnished the bromobenzyl derivative 14, which was then transformed into the organic nitrate 15. 
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Scheme 4. Synthesis of the 4-benzyl nitrate derivative 15. Reagents and conditions: (i) α,α-Dibromo-
p-xylene, K2CO3, dry acetone, reflux, 6 h, 60%; (ii) AgNO3, ACN, reflux, 6 h, 65%; (iii) HCl gas, 
CHCl3, quantitative yield. 
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3.2 Vasodilator and antiplatelet activities 
All the newly synthesized nitric ester derivatives (5a-e, 6a-b, 9 and 15), along with the parent 
compound 1 were assayed to evaluate both the vasodilator and antiplatelet activities; vasorelaxing 
properties of the alcohol products 12a and 12b, hypothetically arising from the cleavage of the nitrate 
function correspondingly in 5b and 5c, were studied as well. The vasodilator activity was evaluated 
on isolated rat aortic strips, precontracted with L-phenylephrine. All the tested compounds showed 
concentration-dependent vasorelaxing effects, and their potencies, expressed as EC50 values, are 
summarized in Table 1. 
The (ONO2)-containing derivatives showed good vasodilatory activity with EC50 values ranging from 
0.01 to 5 µM. The (ONO2)-methyl carbamate 5a and the benzyl nitrate derivative 15 proved to be the 
most potent compounds, with EC50 values falling in the low nanomolar range (13 and 29 nM, 
respectively). The carbamate derivatives 5a and 5b are several times more potent than the 
corresponding amide derivatives 6a and 6b. Within the small carbamate series (5a-d) the vasodilator 
potency is inversely correlated with the length of the alkyl spacer between the ONO2 and >NCOO 
moieties (pEC50/nCH2 points lie on a straight line with slope = -0.84 and r2 = 0.994), suggesting that 
the closer the secondary carbamate group, the greater its electron-withdrawing inductive effect on the 
vasorelaxing activity of the (ONO2)alkyl piperidine-1-carbamate derivatives. 
No substantial change in vasodilatory potency was observed when the NO-donor side-chain was 
elongated, as we did in compound 9, via a link between the terminal 2-(ONO2)acetamido fragment 
and the internal ethyl carbamate group. 
Co-incubation of the aortic strips with the selective inhibitor of sGC, 1H-[1,2,4]oxadiazolo[4,3-
a]quinaxolin-1-one (ODQ), resulted in a rightward shift of the dose-response curves and higher EC50 
values for all the tested nitrate compounds (Fig. 3). The observed decrease of potency provided 
support to NO-mediated activation of sGC, which is the key enzyme modulating smooth muscle 
relaxation (and platelet aggregation as well) through increase of cGMP concentration. Interestingly, 
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also the (ONO2)-lacking compounds 1, 12a and 12b, displayed vasodilatory effects, with EC50 values 
around 20 µM. 
 
Table 1 
In vitro vasodilator and anti-platelet activity of ONO2-substituted compounds and some related 
alcohol derivatives of fluorinated benzyloxyphenyl piperidine-4-carboxamides. 
 Vasodilator activity a Platelet aggregation inhibition b 
Cmpd EC50, µM  SEM 
[+1 µM ODQ] 
 
ADP, 5 µM 
IC50, µM (CL95%) 
[% inhib. ± SEM at 300 µM] 
Collagen, 0.8-1.5 µg/mL 
IC50, µM (CL95%) 
[% inhib. ± SEM at 300 µM] 
1 17 ± 4 73 (68-79) 87 (82-92) 
5a 0.013 ± 0.002 [1.3 ± 0.2] 117 (93-147) [46 ± 6] 
5b 0.11 ± 0.04 [4.5 ± 0.4] 188 (150-236) [11 ± 7] 
5c 0.50 ± 0.08 [3.1 ± 0.8] 180 (129-251) [7.0 ± 4.0] 
5d 5.0 ± 2 [> 100] 234 (198-277) [14 ± 5] 
5e 0.25 ± 0.06 [> 100] 108 (81-146) [41 ± 11] 
6a 0.42 ± 0.06 [17 ± 2] [22 ± 11] [12 ± 5] 
6b 0.49 ± 0.10 [8.5 ± 0.6] [4.0 ± 3.0] [20 ± 13] 
9 0.11 ± 0.02 [14 ± 1] [16 ± 8] [13 ± 4] 
12a 24 ± 5   
12b 23 ± 1   
15 0.029 ± 0.006 [9.3 ± 1.0] 55 (43-70) 194 (182-205) 
a Concentration of tested compound which reduces by 50% contraction of the rat thoracic aortic strips, 
previously treated with 1 M L-phenylephrine, with and without addition of 1 µM ODQ, as sGC 
irreversible selective inhibitor; data are means ± SEM of at least three independent experiments. 
b IC50 values or percent inhibition at the maximum concentration tested (300 M); data are means of 
at least three independent experiments. 
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Fig. 3. Concentration-response curves of 5a (left) and 15 (right), with (●) and without ODQ (○), in 
vasodilation assay on rat aortic strips precontracted with L-phenylephrine. 
 
 
These data suggest, on one hand, that potent vasodilators, like the (ONO2)-methyl carbamate 5a and 
the benzyl nitrate 15, attain smooth muscle relaxation also through mechanisms other than the NO-
mediated prevention of myosin phosphorylation, whereas on the other hand compounds 1 or 12a-b, 
as hypothetic metabolites of the nitrate derivatives 5b-c, retain vasodilatory activity. 
It is known that the smooth muscle relaxation results from a prevention of myosin light chain (MLC) 
phosphorylation, thus maintaining the muscle in the relaxed state, through three main mechanisms: 
(i) increase of cAMP or cGMP leading to phosphorylation, and thereby inhibition, of MLC kinase 
(MLCK); (ii) reduction of intracellular Ca++ concentration and formation of the Ca++-calmodulin 
complex which activates MLCK; (iii) phosphatase-activated MLC dephosphorylation. The 
pharmacological data (Table 1) suggest that the observed vasodilatory effects should mostly depend 
upon the release of NO which activates sGC, ultimately leading to prevention of muscle contraction. 
The significant, albeit poorer, activity shown by compounds 1, 12a and 12b may be most likely 
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related to the capacity of benzyloxy isonipecotanilides of decreasing intracellular Ca++ concentration, 
which also plays a role in regulating smooth muscle contraction; the same mechanism could be 
involved in the residual activity observed for most of the (ONO2)-containing derivatives tested in the 
presence of ODQ. To this purpose, we previously demonstrated that lipophilic nipecotanilides (De 
Marco et al., 2004), similarly to other lipophilic carbamoyl piperidine derivatives (Dillingham et al., 
1989; Feng et al., 1992; Guo et al., 2000), are able to inhibit ADP-induced intraplatelet calcium 
mobilization. It could be reasonably assumed that the lipophilic benzyloxy isonipecotanilide 
derivatives investigated herewith may act by decreasing the intracellular Ca++ concentration also in 
vascular smooth muscle cells. 
Most of the newly synthesized compounds were also evaluated in human platelet-rich plasma (PRP) 
as inhibitors of platelet aggregation induced by 5 μM ADP and collagen (0.8-1.5 µg/ml), using a 
turbidimetric method (Born, 1962). The platelet aggregation inhibition data (Table 1) are expressed 
as the half maximal inhibitory concentrations (IC50, μM), calculated by nonlinear regression of the 
dose-response curves, or % inhibition at the maximum tested concentration (300 μM). Compound 1 
has been re-assayed in this study as a positive control. 
All the tested compounds attained 50% inhibitory activity of the collagen-induced platelet 
aggregation at concentrations significantly higher than those required for inhibiting the ADP-induced 
aggregation. At the tested agonists’ concentrations, we should take into account that platelet 
aggregation triggered by collagen should depend upon the release of arachidonic acid and 
thromboxane A2 (TXA2) generation, while the ADP-induced aggregation should be less TXA2-
dependent. The anti-ADP data point out that the (ONO2)-alkyl carbamate derivatives 5a-e showed at 
least a 1.6-fold loss of antiplatelet potency over the respective parent compounds 1 and 2, proving to 
be in vitro weak-to-moderate antiplatelet agents. Actually, the loss of antiaggregatory potency 
observed is not surprising, taking into account that in general alkyl nitrates decompose very slowly 
in plasma and buffer solution (Jones et al., 2009; Torfgard and Ahlner, 1994; Weber et al., 1993; 
Wendt, 1972). Whatever the rate of hydrolytic cleavage of the carbamates 5a-e in plasma to 
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eventually yield the antiplatelet compounds 1 and 2, and the (ONO2)-substituted alcohol metabolites, 
the experimental results led us to rule out any significant contribution of NO release to the antiplatelet 
activity of the tested nitrates. This is consistent with the activities of non-nitrate compounds 1 and 2, 
which are significantly higher than the corresponding nitrate derivatives, as well as by the generally 
reported failure of platelets to release substantial amounts of NO from organic nitrates in the absence 
of promoters of NO release, such as glutathione (GSH). 
Within the examined series of organic nitrates, the benzyl nitrate derivative 15 and the (ONO2)-
methyl carbamates 5a and 5e are the most potent inhibitors of ADP-induced platelet aggregation. 
However, the antiplatelet IC50 values of the parent 1-unsubstituted isonipecotamides 1 (73 M) and 
2 (27 M), significantly lower than those of any related 1-carbamoyl derivative, combined with that 
of 15 (55 M), highlight the importance of the basicity of the piperidine nitrogen, protonated at 
physiological pH, in order to enhance the platelet aggregation inhibitory potency. Lipophilicity of the 
basic isonipecotamide derivatives should also affect the antiplatelet activity, taking into account that 
the antiplatelet potency of compounds 1, 2 and 15 increase as the estimated log D values at pH 7.4 
(by ACD/Labs software; values in parentheses) increase: 2 (2.22) > 15 (0.56) > 1 (0.47). These SAR 
trends are in reasonable agreement with the supposed mechanism of action of antiplatelet lipophilic 
(iso)nipecotamides (Dillingham et al., 1989; Feng et al., 1992; Guo et al., 2000), which involves 
interaction with anionic phospholipids of the platelet membrane as first step and decrease of 
intraplatelet Ca2+ concentration as final effect resulting in reduction of platelet activation. Indeed, it 
had been shown that, by virtue of their lipophilicity and surface activity, lipophilic nipecotamides can 
penetrate the platelet membranes and interact with anionic phospholipids (mainly 
phosphatidylinositol, PI, and phosphatidylserine, PS), thereby increasing their resistance to 
hydrolysis catalyzed by phospholipase-C to the second messengers inositol 1,4,5-triphosphate (IP3) 
and s,n-1,2-diacylglycerol (DAG) and reducing the concentrations of IP3 and cytosolic Ca2+ under 
the levels required for myosin phosphorylation and platelet activation. In a previous study, we also 
supported such a mechanism proving that a nipecotanilide derivative, almost isolipophilic with those 
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examined herein, inhibits the intraplatelet Ca2+ mobilization induced by ADP, this effect occurring at 
the initial phases of the signal transduction processes in platelets (De Marco et al., 2004). 
 
3.3 Hydrolysis in aqueous media and human serum 
The study of chemical stability focused on the most potent compounds combining good NO-
dependent vasodilatory activities and moderate anti-platelet effects (5a, 5b, 5e and 15) at 37 °C in 
acidic aqueous solution (0.01 M HCl), mimicking gastric environment, and in 0.04 M PBS at pH 7.4. 
In both aqueous media, all the examined compounds underwent pseudo-first-order hydrolysis 
kinetics, exhibiting good stability (half-lives ranging from 5 hours to 7 days). The observed rate 
constants (kobs) and half-lives (t½) are reported in Table 2. 
Although the degradation products of 5a, 5b and 5e were not fully characterized, RP-HPLC 
chromatograms recorded at regular intervals along the monitoring time between t0 and 2×t½ revealed 
disappearance of the carbamate derivatives and appearance of the parent 1-unsubstituted 
isonipecotamides 1 and 2, which result from hydrolysis of the secondary carbamates and subsequent 
rapid CO2 loss by the piperidine-1-carboxylate intermediates. 
 
Table 2 
Kinetic data for hydrolysis in aqueous media and in human serum at 37 °C. a 
 
Cmpd 0.01 M HCl  pH 7.4 PBS  Human serum 
t½ (h) kobs (h-1)  t½ (h) kobs (h-1)  t½ (h) kobs (h-1) 
5a 9.6 0.072  8.3 0.084  9.0 0.077 
5b 110 0.0065  158 0.0045  11 0.063 
5e 14 0.048  20 0.034  2.6 0.27 
15 4.9 0.15  6.2 0.11  2.6 0.27 
a Half-life (t½) and pseudo-first-order rate constant (kobs); values are means from three experiments 
(relative SD < 10%). 
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As a matter of fact, hydrolytic decomposition of 5a and 5b afforded, with significantly different kobs 
values (0.072 and 0.0065 h-1, respectively), predominantly compound 1, whereas 5e afforded 
predominantly the parent compound 2, indicating that in both acidic and pH 7.4 aqueous solutions at 
37 °C the carbamate group underwent hydrolysis faster than the nitric ester group. In case of 5b, the 
related de-nitrated alcohol compound 12a, which was synthesized and used in the stability study as 
analytical standard, was always below the limit of quantitation (LOQ, 3.8 nmol/ml) during the time 
of observation. 
Compared to the (ONO2)methyl carbamate 5a, the rate of decomposition of the more lipophilic analog 
5e decreases by just a factor of 1.5 in 0.01 M HCl and 2.5 in 0.04 M PBS (pH 7.4), most likely due 
to restrictions on the hydration of its transition state. The rate of degradation of the (ONO2)ethyl 
carbamate 5b is ten-to-twenty slower than that of the lower homologue 5a. As expected, the electron-
withdrawing ONO2 group accelerates the rate of hydrolysis of the secondary carbamates with an 
effect stronger on the -carbon (5a) than on the β-carbon (5b). 
The rate of decomposition of the benzyl nitrate derivative 15, which revealed to be less stable than 
5a in both the aqueous media, is just 1.3-fold faster in acidic solution (t½ = 4.9 h) than in solution 
buffered at pH 7.4 (t½ = 6.2 h). 
The stability of the (ONO2)-containing compounds was also studied in human serum at 37 °C (Table 
2). RP-HPLC revealed that also in human serum the main decomposition products of 5a,b and 5e are 
the 1-unsubstituted isonipecotamides 1 and 2, respectively. With the exception of 5a, which showed 
in human serum a stability similar to that measured in the aqueous media, the other carbamate 
derivatives 5b and 5e underwent a faster hydrolysis in serum. The rate of hydrolysis of 5e to the main 
decomposition product 2 is some eight times faster in human serum than in PBS at physiological pH, 
in contrast to its less lipophilic analog 5a which showed not to undergo enzyme-mediated reactions 
in serum (Fig. 4). 
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It has been established that the esterases present in human plasma are butyrylcholinesterase (BuChE), 
paraoxonase (PON1), albumin esterase, and acetylcholinesterase (AChE) in trace amounts, but not 
carboxylesterase; BuChE, PON1 and albumin contribute significantly to ester hydrolysis in human 
plasma (Li et al., 2005). Moreover, it is known that BuChE catalyzes carbamates’ hydrolysis in human 
plasma, and more efficiently binds biaryl-containing substrates and inhibitors (Govoni et al., 2006; 
Lin et al., 2005). The stability data (Table 2) suggest that 5e is a better substrate than 5a for plasma 
esterases, which apparently prefer substrates with larger hydrophobic carbamoyl moieties. 
 
 
 
 
 
 
 
Fig. 4. Plots of first-order kinetics; disappearance of 5a (left) and 5e (right) in pH 7.4 PBS (●) and 
human serum (○) at 37 °C. 
 
 
The times in which the compounds remain within 5% of the initial concentration (t95%), calculated 
from the apparent first-order rate constants in human serum, are equal to 40 and 11 min for 5a and 
5e, respectively, suggesting that the compounds should remain almost intact during the PRP 
aggregation assay. On the other hand, 5a and 5e, which showed in vitro inhibition against the ADP-
induced platelet aggregation with IC50’s around 100 M, decompose in serum, although slowly, to 
yield the more potent anti-platelet compounds 1 (IC50 73 M) and 2 (IC50 27 M). 
The benzyl nitrate derivative 15 was also fairly stable in human serum (t½ 2.6 h). It remains within 
5% of the initial concentration (t95%) for 11 min, suggesting that most of the observed anti-platelet 
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activity (IC50 55 M) can be attributed to the intact (ONO2)-containing molecule. Most likely benzyl 
nitrate 15, similarly to GTN (Govoni et al., 2006), could be slowly hydrolyzed in blood plasma to 
yield the related de-nitrated metabolite. 
 
4. Conclusion 
We synthesized a number of organic nitrate derivatives of recently reported antiplatelet compounds 
1 and 2, built on the structure of benzyloxy isonipecotanilide. As a major outcome of this study, most 
of the investigated (ONO2)-alkyl derivatives showed significant concentration-dependent 
vasodilation effects, as assessed through relaxation of precontracted rat aorta strips, while retaining 
appreciable activity as inhibitors of the ADP-induced platelet aggregation. The pharmacological data 
showed that the newly synthesized organic nitrates, which on the other hand proved to be very stable 
in water at acidic and neutral pH, and quite stable in pooled serum solution, exert their vasorelaxing 
action mainly stimulating the sGC/cGMP pathway, which is known to be damaged in patients with 
heart failure as a consequence of decrease in NO production and bioavailability. In particular, two 
(ONO2)-containing compounds, namely the carbamate-based compound 5a and the benzyl nitrate 
analog 15, proved to be promising for further experimental investigation, including a thorough study 
of the bioactivation and metabolism pathways, as potential medications in the treatment of 
cardiovascular disease (e.g., acute coronary syndrome, angina pectoris, congestive heart failure), as 
they exhibited noteworthy vasodilatory potency in the low nanomolar range (EC50 of 13 and 29 nM, 
respectively) and good antiplatelet activity. 
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